نتایج جستجو برای: biologic therapy
تعداد نتایج: 705849 فیلتر نتایج به سال:
SDZ-ADL is a biosimilar of reference adalimumab. Here, the safety and effectiveness data from British Association Dermatologists Biologic Immuno-modulators Register (BADBIR) are reported. In set, were compared with conventional systemics data. quality-of-life patients treated as first-time biologic, or who switched previous biologic to SDZ-ADL, assessed using Psoriasis Activity Severity Index (...
Systemic therapy for breast cancer is evolving rapidly. The medical treatment of cancer includes chemotherapy, endocrine therapy, and therapy with targeted biologic agents. In the past, a patient’s stage, based on tumor size and nodal involvement, would determine the recommendations for medical therapy, whereas now the biologic features of the tumor direct the treatment plan. As a result of adv...
BACKGROUND Moderate to severe psoriasis, which is defined as psoriasis affecting more than 20% of the body surface area, often requires a combination of therapies to achieve remission. Although numerous data exist regarding the use of acitretin and biologic agent therapy alone for psoriasis, little is known about the efficacy, safety, and tolerability of acitretin combined with biologic agents....
Racial disparities impacting management of psoriasis patients are incompletely understood. The objective this study was to assess biologic discontinuation and switching rates after 6-months therapy among different racial/ethnic backgrounds in the US/Canadian CorEvitas Psoriasis Registry. This included who initiated a between April 2015-March 2021 had known treatment status at follow-up. Patient...
While anatomic imaging (CT and MR imaging) of HNC is focused on diagnosing and/or characterizing the disease, defining its local extent, and evaluating distant spread, accurate assessment of the biologic status of the cancer (cellularity, growth rate, response to nonsurgical chemoradiation therapy, and so forth) can be invaluable for prognostication, planning therapy, and follow-up of lesions a...
GVA Gastroenterologists need to know that biologic agents have been under study for more than 15 years now, and a lot has been learned about their benefits and risks. The anti–tumor necrosis factor (TNF) agents are currently dominating the field of biologic therapy in inflammatory bowel disease (IBD). The armamentarium is relatively small for gastroenterologists compared with that for rheumatol...
OBJECTIVE Due to the increasing use of biologic therapy in rheumatic diseases and the importance of its risk management, the Spanish Society of Rheumatology (SER) has promoted the development of recommendations based on the best evidence available. These recommendations should be a reference to rheumatologists and those involved in the treatment of patients who are using, or about to use biolog...
Drugs form the mainstay of therapy in rheumatoid arthritis (RA). Five main classes of drugs are currently used: analgesics, non-steroidal anti-inflammatories (NSAIDs), glucocorticoids, nonbiologic and biologic disease-modifying antirheumatic drugs. Current clinical practice guidelines recommend that clinicians start biologic agents if patients have suboptimal response or intolerant to one or tw...
Hospitalisation and surgery are considered to be markers of more severe disease in Crohn's disease. These are costly events and limiting these costs has emerged as one rationale for the cost of expensive biologic therapies. The authors sought to review the most recent international literature to estimate current hospitalisation and surgery rates for Crohn's disease and place them in the histori...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید